Abstract: Adjuvant chemotherapy decreases the risk of breast cancer recurrence in patients with breast cancer. In addition, it increases the rate of survival. Therefore, various chemotherapy regimens are administered in the treatment of breast cancer. The efficacy of taxane-based adjuvant chemotherapies has been demonstrated in various trials. This trial was designed to retrospectively evaluate the efficacy of taxane-based chemotherapies in lymph node-positive, early-stage Turkish breast cancer patients. 29 patients receiving TAC regimen and 29 patients receiving AC+P regimen were evaluated. 6 courses of TAC regimen were administered every 3 weeks (docetaxel 75 mg/m², doxorubicine 50 mg/m², cyclophosphamide 500 mg/m²). The other patient group was administered AC+P regimen (4 courses of doxorubicin 60mg/m², cyclophosphamide 600 mg/m² combination every 2 weeks, followed by paclitaxel 175 mg/m² for 4 courses every 2 weeks). The 1-year, 2-year and 3-year disease-free survival (DFS) rates were 96.3%, 81.1% and 72.8% respectively. No significant difference was detected in DFS between premenopausal and postmenopausal patients on the taxane regimen (p=0.82).
Introduction
Breast cancer is the most common malignity observed in females in the USA. In 2008, 182000 new cases and 41000 deaths due to breast cancer were reported in the USA [1] . In breast cancer patients, adjuvant chemotherapy decreases the breast cancer recurrence risk. In addition, it increases the rate of survival. Therefore, various chemotherapy regimens are administered in the treatment of breast cancer. Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen is the first modern combination regimen and it is currently used, particularly in patients with cardiac disorder.
Anthracyclines have been introduced to medical use to enhance therapeutical efficacy. Cyclophosphamidedoxorubicin (AC), 5-fluorouracil-doxorubicincyclophosphamide (FAC), 5-fluorouracil-epirubicincyclophosphamide (FEC) and cyclophosphamideepirubicin (EC) are the anthracycline combinations used [3] . Another drug group with an important place in the systemic treatment of breast cancer is taxanes. Taxanes (docetaxel, paclitaxel) are agents with high efficacy in the treatment of breast cancer through their mode of action on the microtubule system. They provide a response rate of 25-69% in the first-line therapy of metastatic breast cancer and in addition, their probability of showing cross-resistance to anthracyclines is low, which constitutes another advantage [4] . These results have led to the use of taxanes also in the adjuvant treatment of early-stage breast cancer and in the recent years, many adjuvant treatment studies have been performed involving different doses and administration routes.
This trial was designed to retrospectively evaluate the efficacy of taxane-based chemotherapies in lymph node-positive, early-stage breast cancer patients. 
Material and Methods

Patients
Treatment
Patients received two different taxane-based chemotherapy regimens. 6 courses of TAC regimen were administered every 3 weeks (docetaxel 75 mg/m², doxorubicine 50 mg/m², cyclophosphamide 500 mg/m²). The other patient group was administered AC+P regimen (4 courses of doxorubicin 60mg/m², cyclophosphamide 600 mg/m² combination every 2 weeks, followed by paclitaxel 175 mg/m² for 4 courses every 2 weeks). In patients receiving both chemotherapy regimens, prophylactic granulocyte -colony-stimulating factor administration was performed. Patients were evaluated by physical examination and blood investigations before each chemotherapy course. Criteria of eligibility for inclusion in the trial were as follows: white sphere count > 3.0, neutrophil count > platelet count > 100.00, bilirubin at normal limits, and transaminase (AST, ALT) < 1.5-fold of normal limits. Prior to treatment, left ventricular ejection fraction was determined to be normal in all patients. NCI Common Toxicity Criteria was used for evaluating treatment-associated toxicities.
Statistical method
Statistical analysis including survival analysis was performed with the SPSS 10 software package program. Disease free survival (DFS) was calculated from the first day of treatment to clinical/radiological evidence(s) of recurrence. The Kaplan-Meier method (Log rank analysis) was used for the survival analysis. All differences were considered non-significant when p-values were greater than 0.05.
Results
Patient characteristics
29 patients receiving TAC regimen and 29 patients receiving AC+P regimen were evaluated. While the mean age of those on TAC regimen was 49.9±10.2, those on AC+P regimen had a mean age of 49.1±9.8. The majority of the patients receiving both treatment regimens consisted of premenopausal patients. In addition, most of the patients were ER/PR positive patients in both treatment arms. HER-2 positive patients (2 patients receiving TAC and 4 patients receiving AC+P) had not received adjuvant trastuzumab treatment.
While most of the patients receiving TAC treatment were at stage II, the majority of patients on AC+P were at Stage III. Hormone receptor positive patients had received adjuvant hormone therapy. Demographic characteristics and disease-related characteristics of the patients are summarized in Table 1 .
Toxicity
Patients in both treatment arms received their treatment course completely (TAC, 6 courses; AC+P, 8 courses). One patient in the TAC treatment arm and one patient in the AC+P treatment arm were observed to have grade 3 leucopenia. Patients did not experience neutropenic fever attack. These two patients had a one-week delay in treatment. No treatment-related mortality occurred in either group.
Response to treatment
Evaluation of all patients receiving taxane-based chemotherapy revealed 1-year, 2-year and 3-year disease-free survival (DFS) rates of 96.3%, 81.1% and 72.8% respectively ( Table 2) .
DFS was assessed by menopausal status. No significant difference was detected in DFS between premenopausal and postmenopausal patients on the taxane regimen (p=0.82) (Figure 1 ). There was no significant difference in DFS between estrogen or progesterone receptor positive and negative patients (p=0.46) (Figure 2) . Disease-free survival was compared between patients receiving TAC and AC+P adjuvant chemotherapy regimens. The follow-up period of patients on AC+P chemotherapy was longer than those receiving TAC (AC+P mean 38.6±12.8 months, TAC mean 17.1±5.4 months). Three and 8 of the patients receiving TAC and AC+P respectively developed recurrence. Three patients on TAC recurred with distant metastasis (bone and liver metastases). While 1 of the patients receiving AC+P treatment regimen developed both local and distant metastasis, the other 7 patients developed distant metastasis (lung, liver, bone, and brain metastases). No significant difference was detected between the two treatment arms with respect to DFS (p=0.92) (Figure 3 
Discussion
Taxane combinations have been first used in combination with standard anthracycline-based chemotherapy in the adjuvant treatment of early-stage breast cancer. The comparison of chemotherapy regimens ranging from combinations of paclitaxel and docetaxel with anthracyclines to anthracycline-based chemotherapy revealed significant improvement in the overall response rate and time to progression [5] .
In the current trial, two taxane-based chemotherapy agents (paclitaxel and docetaxel) were used in different combinations. Docetaxel was administered in combination with TAC for 6 courses while paclitaxel was administered following 4 courses of AC in 4 courses. The first trial to administer paclitaxel sequentially was the Cancer and Leukemia Group B (CALGB) 9344 study, in which 3170 node (+) breast cancer patients were randomized to receive 4 courses of AC chemotherapy consisting of three different doxorubicin doses (60, 75 or 75 mg/m 2 ) and cyclophosphamide (600mg/m 2 ) first, followed by 4 courses of paclitaxel (175 mg/m 2 ) or followup arms. A median follow-up of 69 months detected better disease-free survival and overall survival in the arm receiving additional paclitaxel (respectively, 70% vs 65%, p=0.0023 and 80% vs 77%, p=0.0064) [6] .
In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial, 3060 node (+) breast cancer patients were randomized to receive 4 cycles of AC (60/600 mg/m 2 ) alone or 4 cycles of AC chemotherapy followed by 4 cycles of paclitaxel (225 mg/m 2 ). Median follow-up of 34 months detected no difference between the two treatment arms with respect to both diseasefree and overall survival; however the results after 65 months revealed a disease-free survival rate reaching significance (5 years, 76% vs 72%, p=0.008) and no difference in overall survival (5 years, 85% vs 85%) [7] . In the Breast Cancer International Research Group (BCIRG) 001 trial using docetaxel in combination treatment, 1491 node (+) patients were randomized to 6 courses of FAC (500/50/500 mg/m 2 ) or 6 courses of docetaxel, doxorubicin and cyclophosphamide (TAC) (75/50/500 mg/m 2 ) regimen following completion of primary locoregional treatment. A median follow-up of 55 months detected both disease-free and overall survival to be statistically significantly better in favor of TAC (5-year HSK 75% vs 68%, p=0.001 and 5-year GSK 87% vs 81%, p=0.008) [8] .
Considering the short duration of follow-up in patients receiving 4AC+P or 6TAC and the small number of patients in our trial, the 2-year disease-free survival rates of 82% and 84.9% were similar to the literature.
Sequential administration of taxanes was reported to be advantageous compared to concomitant administration [9] . Although there are a few trials comparing taxanes with each other, the ECOG 1199 trial demonstrated that there was no significant difference between node (+) and high-risk node (-) patients in the efficacy of taxanes added to adjuvant treatment [10] .
Our trial also compared both treatment arms with respect to efficacy despite different ER/PS status, node status and follow-up periods. No difference in diseasefree survival was detected between the two treatment arms (p=0.92). The limitation of anthracycline and taxane combinations is their hematologic toxicities [5, 11] . Two of our patients (3%) developed treatment-related neutropenia. However, patients did not experience neutropenic fever. These results were attributed to prophylactic G-CSF use. The menopausal status of patients was detected to have no significant effect on disease-free survival (p=0.82).
In a trial by Berry DA et al involving 6644 node (+) patients, the efficacy of three different regimens administered as adjuvant chemotherapy on ER (+) and ER (-) tumors was investigated. This trial reported that ER (-) tumors benefited more from adjuvant chemotherapy as compared to ER (+) tumors (absolute gain in 5-year disease-free survival: 22.8% vs 7.0%; and the reduction in total mortality: 55% vs 23%). Doxorubicin, cyclophosphamide and paclitaxel regimen administered every 2 weeks provided 50% more reduction in recurrence and mortality rates compared to low-dose CAF regimen [12] .
As for the current trial, evaluation of patients by their ER/PR status revealed no significant difference between the two groups in disease-free survival (p=0.46). These results may be attributable to the small number of patients.
In conclusion, this trial once more demonstrated that taxane-based adjuvant chemotherapy was effective and safe in lymph node-positive, early-stage Turkish breast cancer patients.
